Double maintains 2 strategies that include BPMC - Blueprint Medicines Corp.
| Name | Correlation | AUM | Expense Ratio |
|---|---|---|---|
| XBI | 48.00% | $4.90B | 0.35% |
| PBE | 46.08% | $228.63M | 0.58% |
| IBB | 45.62% | $5.44B | 0.45% |
| IWO | 41.45% | $11.87B | 0.24% |
| GNOM | 39.82% | $46.32M | 0.5% |
| FBT | 39.57% | $1.02B | 0.54% |
| KJAN | 39.47% | $287.30M | 0.79% |
| IWM | 39.42% | $66.85B | 0.19% |
| TMSL | 39.40% | $852.85M | 0.55% |
| IWMY | 39.29% | $121.39M | 1.02% |
| XPH | 39.23% | $150.90M | 0.35% |
| VTWO | 39.06% | $12.85B | 0.07% |
| PTH | 39.04% | $97.73M | 0.6% |
| BBH | 38.96% | $340.09M | 0.35% |
| ACIO | 38.96% | $1.99B | 0.79% |
| PSC | 38.91% | $773.39M | 0.38% |
| HELO | 38.76% | $3.30B | 0.5% |
| VBK | 38.64% | $19.31B | 0.07% |
| ISCG | 38.58% | $694.97M | 0.06% |
| SCHA | 38.44% | $17.76B | 0.04% |
| Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
|---|---|---|---|---|
| KYMR | 55.42% | $3.05B | +10.12% | 0.00% |
| VERA | 52.64% | $1.47B | -34.40% | 0.00% |
| NRIX | 45.30% | $930.84M | -41.33% | 0.00% |
| APLS | 43.54% | $2.25B | -52.34% | 0.00% |
| STLD | 43.00% | $20.20B | +9.49% | 1.41% |
| TBPH | 41.77% | $561.01M | +25.78% | 0.00% |
| MODV | 41.64% | $55.41M | -83.48% | 0.00% |
| BDTX | 41.18% | $142.16M | -50.10% | 0.00% |
| IDYA | 40.49% | $1.88B | -44.46% | 0.00% |
| DRS | 40.40% | $12.36B | +78.96% | 0.39% |
| BBIO | 38.80% | $8.20B | +68.05% | 0.00% |
| PLAB | 38.70% | $1.20B | -21.51% | 0.00% |
| CLF | 38.64% | $4.39B | -41.50% | 0.00% |
| IONS | 38.54% | $6.58B | -12.12% | 0.00% |
| ROIV | 38.51% | $7.38B | +0.28% | 0.00% |
| APG | 38.23% | $14.39B | +41.12% | 0.00% |
| NUE | 38.08% | $32.24B | -7.00% | 1.57% |
| COHR | 37.87% | $14.05B | +20.36% | 0.00% |
| CENX | 37.87% | $1.73B | -0.38% | 0.00% |
| ARWR | 37.50% | $2.42B | -30.81% | 0.00% |
| Name | Correlation | AUM | Expense Ratio |
|---|---|---|---|
| BTAL | -33.65% | $312.42M | 1.43% |
| VIXY | -32.62% | $185.99M | 0.85% |
| TAIL | -32.47% | $95.09M | 0.59% |
| SPTS | -18.77% | $5.77B | 0.03% |
| VGSH | -17.64% | $22.64B | 0.03% |
| UTWO | -17.36% | $376.38M | 0.15% |
| SCHO | -16.50% | $11.00B | 0.03% |
| IVOL | -16.10% | $342.02M | 1.02% |
| IBTH | -15.36% | $1.61B | 0.07% |
| IBTI | -15.35% | $1.06B | 0.07% |
| XONE | -14.12% | $627.68M | 0.03% |
| IBTG | -14.11% | $1.92B | 0.07% |
| IEI | -13.29% | $15.58B | 0.15% |
| SHY | -12.99% | $23.60B | 0.15% |
| IBTJ | -12.61% | $682.49M | 0.07% |
| ULST | -12.46% | $595.49M | 0.2% |
| VGIT | -12.43% | $31.66B | 0.04% |
| IBTK | -12.30% | $446.70M | 0.07% |
| STXT | -12.09% | $128.76M | 0.49% |
| BSV | -11.42% | $37.94B | 0.03% |
| Name | Correlation | AUM | Expense Ratio |
|---|---|---|---|
| SHYD | <0.01% | $331.76M | 0.35% |
| SCHJ | <0.01% | $528.58M | 0.03% |
| TFI | 0.02% | $3.22B | 0.23% |
| SHM | 0.02% | $3.40B | 0.2% |
| TLTW | -0.03% | $1.15B | 0.35% |
| PZA | -0.04% | $2.84B | 0.28% |
| UNG | -0.05% | $378.37M | 1.06% |
| BSCR | 0.05% | $3.71B | 0.1% |
| BSMW | -0.07% | $107.54M | 0.18% |
| VTEB | -0.09% | $37.79B | 0.03% |
| SCMB | -0.10% | $2.09B | 0.03% |
| TIPZ | 0.12% | $94.09M | 0.2% |
| JMUB | 0.14% | $3.06B | 0.18% |
| BSCT | 0.16% | $2.12B | 0.1% |
| VCSH | -0.16% | $34.18B | 0.03% |
| PFFR | -0.18% | $94.66M | 0.45% |
| IBDX | -0.21% | $1.16B | 0.1% |
| GSY | 0.21% | $2.89B | 0.22% |
| SCHP | 0.26% | $12.92B | 0.03% |
| IBDV | 0.32% | $1.90B | 0.1% |
| Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
|---|---|---|---|---|
| TAP | 0.03% | $9.50B | -1.12% | 3.69% |
| CNK | 0.08% | $3.52B | +41.39% | 0.53% |
| CHE | 0.08% | $6.82B | -11.73% | 0.43% |
| WDFC | 0.12% | $3.11B | +4.06% | 1.58% |
| INSP | -0.13% | $3.94B | +1.53% | 0.00% |
| UPLD | -0.15% | $57.54M | -13.86% | 0.00% |
| CHD | 0.16% | $24.14B | -6.28% | 1.18% |
| LFVN | 0.17% | $177.75M | +150.80% | 1.17% |
| RGR | 0.21% | $599.29M | -11.49% | 1.99% |
| NEUE | 0.24% | $60.98M | +32.62% | 0.00% |
| NATR | 0.32% | $290.80M | +10.45% | 0.00% |
| GO | 0.35% | $1.26B | -40.31% | 0.00% |
| BTCT | 0.48% | $25.33M | +62.02% | 0.00% |
| CLLS | 0.53% | $116.07M | -15.93% | 0.00% |
| CMTL | 0.53% | $74.08M | -16.83% | 0.00% |
| CCI | 0.58% | $44.67B | +5.69% | 5.66% |
| KO | -0.59% | $302.33B | +12.04% | 2.84% |
| TEF | 0.62% | $29.46B | +22.82% | 6.25% |
| CIG.C | -0.64% | $2.65B | +23.47% | 0.00% |
| SLP | 0.64% | $352.14M | -55.75% | 0.34% |
| Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
|---|---|---|---|---|
| LITB | -10.09% | $23.17M | -74.54% | 0.00% |
| K | -9.83% | $27.53B | +40.77% | 2.87% |
| PPC | -9.25% | $10.85B | +36.15% | 0.00% |
| ED | -9.09% | $35.78B | +11.77% | 3.38% |
| T | -7.98% | $203.56B | +50.48% | 3.92% |
| HOLX | -7.80% | $14.46B | -13.18% | 0.00% |
| TXMD | -7.07% | $13.66M | -33.71% | 0.00% |
| PULM | -6.95% | $23.96M | +218.45% | 0.00% |
| CABO | -6.86% | $751.19M | -58.53% | 6.60% |
| VZ | -6.76% | $181.55B | +4.26% | 6.29% |
| CL | -5.95% | $74.67B | -5.05% | 2.19% |
| AWK | -5.60% | $27.50B | +7.88% | 2.23% |
| SAIC | -5.37% | $5.49B | +3.32% | 1.26% |
| BDX | -5.13% | $50.05B | -21.15% | 2.33% |
| CBOE | -5.01% | $24.35B | +37.95% | 1.09% |
| AMT | -4.98% | $103.32B | +12.63% | 3.03% |
| SBAC | -4.98% | $25.17B | +19.80% | 1.79% |
| CAG | -4.78% | $9.86B | -28.15% | 6.76% |
| IMDX | -4.71% | $83.22M | -2.68% | 0.00% |
| CARV | -4.11% | $8.88M | +17.45% | 0.00% |
Current Value
$128.471 Year Return
Current Value
$128.471 Year Return
Yahoo
The United States market has shown robust performance, climbing 1.9% in the last 7 days and 12% over the past year, with earnings forecasted to grow by 14% annually. In this environment, identifying high growth tech stocks involves looking for companies that demonstrate strong innovation potential and resilience in their financial metrics.
Yahoo
Blueprint Medicines Corporation (NASDAQ:BPMC) is one of the best biotech stocks to invest in now. On June 12, Blueprint Medicines announced new data reinforcing the sustained clinical efficacy and well-tolerated safety profile of long-term AYVAKIT/AYVAKYT (avapritinib) treatment. These findings were presented at the 2025 European Hematology Association Hybrid Congress, which was held from June 12-15, […]
Yahoo
The United States market has remained flat over the past week but has shown a 10.0% increase over the past year, with earnings projected to grow by 15% annually. In this context, identifying high-growth tech stocks involves focusing on companies that demonstrate strong potential for revenue expansion and innovation in line with these optimistic earnings forecasts.
Finnhub
Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC are investigating the proposed sale of Blueprint Medicines Corporation to Sanofi . Under...
Yahoo
In the last week, the United States market has been flat, yet it is up 9.9% over the past year with earnings projected to grow by 15% annually. In this context of steady growth and positive earnings forecasts, identifying high-growth tech stocks involves looking for companies that demonstrate strong innovation potential and robust financial health amidst these conditions.
SeekingAlpha
Sanofi acquires Blueprint Medicines Corporation for $9.1bn, gaining revenue-driving Aykavit and pipeline drug BLU-808 potential. Click for more on SNY and BPMC.
